Search

Your search keyword '"Ouyang, Quchang"' showing total 329 results
Start Over Author "Ouyang, Quchang"
329 results on '"Ouyang, Quchang"'

3. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Author

Jiang, Zefei, Ouyang, Quchang, Sun, Tao, Zhang, Qingyuan, Teng, Yuee, Cui, Jiuwei, Wang, Haibo, Yin, Yongmei, Wang, Xiaojia, Zhou, Xin, Wang, Yongsheng, Sun, Gang, Wang, Jingfen, Zhang, Lili, Yang, Jin, Qian, Jun, Yan, Min, Liu, Xinlan, Yi, Tienan, Cheng, Ying, Li, Man, Zang, Aimin, Wang, Shusen, Wang, Chuan, Wu, Xinhong, Cheng, Jing, Li, Hui, Lin, Ying, Geng, Cuizhi, Gu, Kangsheng, Xie, Chunwei, Xiong, Huihua, Wu, Xiaohong, Yang, Junlan, Li, Qingshan, Chen, Yiding, Li, Fanfan, Zhang, Anqin, Zhang, Yongqiang, Wu, Yudong, Nie, Jianyun, Liu, Qiang, Wang, Kun, Mo, Xueli, Chen, Lilin, Pan, Yueyin, Fu, Peifen, Zhang, Helong, Pang, Danmei, Sheng, Yuan, Han, Yunwei, Wang, Hongxia, Cang, Shundong, Luo, Xianming, Yu, Wenbo, Deng, Rong, Yang, Chaoqiang, and Keegan, Patricia

Published
2024
Full Text
View/download PDF

4. Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial

Author

Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong, Liu, Zhenzhen, Lv, Huimin, Zhang, Mengwei, Liu, Liping, Yang, Xiaohong, Xiao, Huawu, Gao, Zhichao, Li, Xiaorui, Dong, Fangyuan, Zhang, Lingxiao, Dong, Danfeng, Chen, Xiuchun, Qiao, Jianghua, Zhang, Guifang, Zeng, Huiai, Wang, Jing, Sun, Huihui, Feng, Yajing, Chen, Yuting, and Xia, Fangzhou

Published
2024
Full Text
View/download PDF

9. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Author

Xu, Binghe, Sun, Tao, Shi, Yanxia, Cui, Jiuwei, Yin, Yongmei, Ouyang, Quchang, Liu, Qiang, Zhang, Qingyuan, Chen, Yiding, Wang, Shouman, Wang, Xiaojia, Tong, Zhongsheng, Zhong, Yahua, Wang, Jiayu, Yan, Min, Yan, Xi, Wang, Chuan, Feng, Jifeng, Wang, Xiuli, Hu, Gang, Cheng, Ying, Ge, Ruimin, Zhu, Zhaoyin, Zhang, Wa, and Shao, Zhimin

Published
2023
Full Text
View/download PDF

11. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Author

Xu, Binghe, Zhang, Qingyuan, Hu, Xichun, Li, Qing, Sun, Tao, Li, Wei, Ouyang, Quchang, Wang, Jingfen, Tong, Zhongsheng, Yan, Min, Li, Huiping, Zeng, Xiaohua, Shan, Changping, Wang, Xian, Yan, Xi, Zhang, Jian, Zhang, Yue, Wang, Jiani, Zhang, Liang, Lin, Ying, Feng, Jifeng, Chen, Qianjun, Huang, Jian, Zhang, Lu, Yang, Lisong, Tian, Ying, and Shang, Hongyan

Published
2023
Full Text
View/download PDF

13. Computer-aided diagnosis of lung carcinoma using deep learning - a pilot study

Author

Li, Zhang, Hu, Zheyu, Xu, Jiaolong, Tan, Tao, Chen, Hui, Duan, Zhi, Liu, Ping, Tang, Jun, Cai, Guoping, Ouyang, Quchang, Tang, Yuling, Litjens, Geert, and Li, Qiang

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Aim: Early detection and correct diagnosis of lung cancer are the most important steps in improving patient outcome. This study aims to assess which deep learning models perform best in lung cancer diagnosis. Methods: Non-small cell lung carcinoma and small cell lung carcinoma biopsy specimens were consecutively obtained and stained. The specimen slides were diagnosed by two experienced pathologists (over 20 years). Several deep learning models were trained to discriminate cancer and non-cancer biopsies. Result: Deep learning models give reasonable AUC from 0.8810 to 0.9119. Conclusion: The deep learning analysis could help to speed up the detection process for the whole-slide image (WSI) and keep the comparable detection rate with human observer.

Published
2018

17. Optimize transfer learning for lung diseases in bronchoscopy using a new concept: sequential fine-tuning

Author

Tan, Tao, Li, Zhang, Liu, Haixia, Liu, Ping, Tang, Wenfang, Li, Hui, Sun, Yue, Yan, Yusheng, Li, Keyu, Xu, Tao, Wan, Shanshan, Lou, Ke, Xu, Jun, Ying, Huiming, Ouyang, Quchang, Tang, Yuling, Hu, Zheyu, and Li, Qiang

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Bronchoscopy inspection as a follow-up procedure from the radiological imaging plays a key role in lung disease diagnosis and determining treatment plans for the patients. Doctors needs to make a decision whether to biopsy the patients timely when performing bronchoscopy. However, the doctors also needs to be very selective with biopsies as biopsies may cause uncontrollable bleeding of the lung tissue which is life-threaten. To help doctors to be more selective on biopsies and provide a second opinion on diagnosis, in this work, we propose a computer-aided diagnosis (CAD) system for lung diseases including cancers and tuberculosis (TB). The system is developed based on transfer learning. We propose a novel transfer learning method: sentential fine-tuning . Compared to traditional fine-tuning methods, our methods achieves the best performance. We obtained a overall accuracy of 77.0% a dataset of 81 normal cases, 76 tuberculosis cases and 277 lung cancer cases while the other traditional transfer learning methods achieve an accuracy of 73% and 68%. . The detection accuracy of our method for cancers, TB and normal cases are 87%, 54% and 91% respectively. This indicates that the CAD system has potential to improve lung disease diagnosis accuracy in bronchoscopy and it also might be used to be more selective with biopsies.

Published
2018

19. A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.

Author

Jiang, Zefei, Ouyang, Quchang, Sun, Tao, Zhang, Qingyuan, Teng, Yuee, Cui, Jiuwei, Wang, Haibo, Yin, Yongmei, Wang, Xiaojia, Zhou, Xin, Wang, Yongsheng, Sun, Gang, Wang, Jingfen, Zhang, Lili, Yang, Jin, Qian, Jun, Yan, Min, Liu, Xinlan, Yi, Tienan, and Cheng, Ying

Abstract

Plain Language Summary What is this summary about? This summary describes interim (not final) results of a clinical study called TORCHLIGHT. The study looked at the effect of a medicine called toripalimab when added to standard chemotherapy in women with triple-negative breast cancer (TNBC) that has come back after being treated ('recurrent TNBC') or has spread to other parts of the body ("metastatic TNBC"). Chemotherapy has been a cornerstone of treatment for recurrent and metastatic TNBC, although it has limited efficacy (ability to produce a desired or intended result). Recent evidence suggests that adding a certain type of immunotherapy (a medicine that boosts the ability of the body's immune system to kill cancer cells) may improve survival among women with recurrent or metastatic TNBC. Researchers wanted to see whether toripalimab added to standard chemotherapy was safe and effective for increasing the amount of time women with newly diagnosed recurrent or metastatic TNBC could live without their cancer getting worse (a measurement called 'progression-free survival'). Researchers looked at the safety and efficacy of adding toripalimab among all women with recurrent or metastatic TNBC included in the TORCHLIGHT study, and separately, among a particular subgroup whose breast tumors had a specific protein on their surface called programmed death ligand 1 (PD-L1); these patients are referred to as having 'PD-L1-positive TNBC'. What are the key takeaways? Interim results from the TORCHLIGHT study showed that women with PD-L1-positive recurrent or metastatic TNBC treated with toripalimab plus standard chemotherapy had significantly longer progression-free survival than those who received standard chemotherapy alone. The treatment groups with and without toripalimab had similar rates of side effects (an effect of a medicine that is beyond its desired effect and can be harmful), which are tracked to assess safety. What were the main conclusions reported by the researchers? Researchers concluded that results of the TORCHLIGHT study showed that women with PD-L1-positive recurrent or metastatic TNBC treated with toripalimab and chemotherapy lived longer without their TNBC getting worse than women treated with chemotherapy alone, results which support the addition of toripalimab to chemotherapy in women with PD-L1-positive recurrent or metastatic TNBC. Who is this summary for? This summary is intended to provide information to women with recurrent or metastatic TNBC and their family members or caregivers. It may also be helpful for patient advocates and health care professionals. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

21. Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer.

Author

Liu, Binliang, Hu, Zhe‐Yu, Xie, Ning, Liu, Liping, Li, Jing, Yang, Xiaohong, Xiao, Huawu, Zhao, Xuran, Tian, Can, Wu, Hui, Lu, Jun, Gao, Jianxiang, Hu, Xuming, Cao, Min, Shui, Zhengrong, Tang, Yu, and Ouyang, Quchang

Subjects
METASTATIC breast cancer, CYCLIN-dependent kinase inhibitors, TERMINATION of treatment, ESTROGEN receptors, PROGESTERONE receptors
Abstract

Background: CDK4/6 inhibitors (CDK4/6i) have shown promising results in the treatment of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) when combined with endocrine therapy (ET). It is crucial to evaluate the actual effectiveness and safety of CDK4/6i in clinical practice, as well as to analyze the factors that can predict their outcomes. Methods: Patients with HR+ MBC who received CDK4/6i‐based therapy between May 2016 and May 2023 at Hunan Cancer Hospital were evaluated for progression‐free survival (PFS). Adverse reactions were assessed based on the National Cancer Institute Common Toxicity Criteria (version 5.0). Results: This study included 344 patients, with a median PFS (mPFS) of 12.8 months (range: 10.4–15.2 months). After adjustment, Cox multivariate regression analysis revealed that visceral metastasis (specifically liver and brain metastases), Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 1, estrogen receptor ≤ 80%, progesterone receptor ≤ 10%, Ki‐67 > 30%, and treatment in later stages were significant factors associated with reduced PFS. Based on this, we created a prognostic nomogram and validated its performance, obtaining a C‐index of 0.714 (95% confidence interval: 0.640–0.787) as well as reliable calibration and clinical impact. The mPFS of CDK4/6i rechallenge was 7.7 months; for patients who initially discontinued CDK4/6i for reasons other than disease progression, CDK4/6i rechallenge still provided a mPFS of 11.4 months. The tolerability and safety of combining CDK4/6is with ET were manageable. Adverse events led to treatment discontinuation in 3.8% of patients. Neutropenia (29.1%), leukopenia (13.7%), and anemia (4.1%) were the primary grade 3/4 adverse reactions. Conclusions: This real‐world study highlights the ample efficacy and reasonable safety of combined CDK4/6i and ET in patients with HR+ MBC. Individualized treatment decisions and ongoing safety monitoring are important to optimize the therapeutic benefit of CDK4/6i treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

Author

Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong, Orlandi, Armando, Ishii, Naohiro, Takabe, Kazuaki, Franceschini, Gianluca, Ricci, Francesco, Verschraegen, Claire, Liu, Zhenzhen, Zhang, Mengwei, Lv, Huimin, Liu, Liping, Yang, Xiaohong, Xiao, Huawu, Gao, Zhichao, Li, Xiaorui, Dong, Fangyuan, Chen, Xiuchun, Qiao, Jianghua, and Zhang, Guifang

Published
2022
Full Text
View/download PDF

24. Bireociclib plus fulvestrant for advanced HR+/HER2- breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2).

Author

Wang, Jiayu, primary, Zhang, Qingyuan, additional, Li, Huiping, additional, Tong, Zhongsheng, additional, Ouyang, Quchang, additional, Li, Huihui, additional, Teng, Yuee, additional, Wang, Biyun, additional, Sun, Tao, additional, Wang, Jingfen, additional, Li, Wei, additional, Niu, Zhaofeng, additional, Li, Hongsheng, additional, Gong, Chang, additional, Wang, Li, additional, Liu, Fei, additional, Wang, Shuya, additional, Meng, Yaping, additional, Duan, Xianghui, additional, and Xu, Binghe, additional

Published
2024
Full Text
View/download PDF

25. Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.

Author

Yang, Benlong, primary, Geng, Cuizhi, additional, Sun, Zhengkui, additional, Ouyang, Quchang, additional, Wang, Haibo, additional, Tong, Zhongsheng, additional, Wang, Shu, additional, Li, Hongyuan, additional, Niu, Zhaofeng, additional, Chen, Yiding, additional, Ma, Lin-Xiaoxi, additional, and Wu, Jiong, additional

Published
2024
Full Text
View/download PDF

26. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

Author

Xu, Binghe, primary, Yin, Yongmei, additional, Fan, Ying, additional, Ouyang, Quchang, additional, Song, Lihua, additional, Wang, Xiaojia, additional, Li, Wei, additional, Li, Man, additional, Yan, Xi, additional, Wang, Shusen, additional, Sun, Tao, additional, Teng, Yuee, additional, Tang, Xianjun, additional, Tong, Zhongsheng, additional, Sun, Zhengkui, additional, Jin, Xiaoping, additional, Diao, Yina, additional, Liu, Gesha, additional, and Ge, Junyou, additional

Published
2024
Full Text
View/download PDF

27. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.

Author

Wang, Jiani, primary, Zhang, Qingyuan, additional, Hu, Xichun, additional, Li, Qing, additional, Sun, Tao, additional, Li, Wei, additional, Ouyang, Quchang, additional, Wang, Jingfen, additional, Tong, Zhongsheng, additional, Yan, Min, additional, Li, Huiping, additional, Zeng, Xiaohua, additional, Shan, Changping, additional, Wang, Xian, additional, Zhang, Jian, additional, Zhang, Yue, additional, Zhang, Liang, additional, Tian, Ying, additional, Shang, Hongyan, additional, and Xu, Binghe, additional

Published
2024
Full Text
View/download PDF

28. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Author

Xu, Binghe, Zhang, Qingyuan, Zhang, Pin, Hu, Xichun, Li, Wei, Tong, Zhongsheng, Sun, Tao, Teng, Yuee, Wu, Xinhong, Ouyang, Quchang, Yan, Xi, Cheng, Jing, Liu, Qiang, Feng, Jifeng, Wang, Xiaojia, Yin, Yongmei, Shi, Yanxia, Pan, Yueyin, Wang, Yongsheng, Xie, Weimin, Yan, Min, Liu, Yunjiang, Yan, Ping, Wu, Fei, Zhu, Xiaoyu, and Zou, Jianjun

Published
2021
Full Text
View/download PDF

30. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Author

Xu, Binghe, Yan, Min, Ma, Fei, Hu, Xichun, Feng, Jifeng, Ouyang, Quchang, Tong, Zhongsheng, Li, Huiping, Zhang, Qingyuan, Sun, Tao, Wang, Xian, Yin, Yongmei, Cheng, Ying, Li, Wei, Gu, Yuanting, Chen, Qianjun, Liu, Jinping, Cheng, Jing, Geng, Cuizhi, Qin, Shukui, Wang, Shusen, Lu, Jinsong, Shen, Kunwei, Liu, Qiang, Wang, Xiaojia, Wang, Hong, Luo, Ting, Yang, Jin, Wu, Yudong, Yu, Zhiyong, Zhu, Xiaoyu, Chen, Chunxia, and Zou, Jianjun

Published
2021
Full Text
View/download PDF

32. Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study.

Author

Zhang, Qingyuan, Shen, Kunwei, Song, Chuan-gui, Ouyang, Quchang, Liu, Zhenzhen, Liu, Qiang, Feng, Jifeng, Chiu, Joanne W. Y., Tang, Jinhai, Jiang, Zefei, Tseng, Ling-Ming, Wang, Xiaojia, Yang, Liu, Qian, Chenxi, and Shao, Zhimin

Abstract

Background: Abemaciclib was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved globally in the adjuvant setting for high-risk hormone-receptor positive (HR+)/human epidermal growth factor 2 negative (HER2−) early breast cancer (EBC), based on the phase III monarchE trial. Objective: To report an exploratory Chinese population analysis based on the preplanned overall survival (OS) interim analysis with 5-year efficacy results of monarchE. Design and methods: Patients with HR+/HER2−, high-risk (⩾4 positive lymph nodes, or 1–3 nodes and either tumor size ⩾5 cm, histologic grade 3, or Ki-67 ⩾20%) EBC were randomized (1:1) to abemaciclib (150 mg twice daily for 2 years) plus endocrine therapy (ET), or ET alone. This analysis included Chinese patients enrolled in mainland China, Hong Kong, and Taiwan. The primary endpoint was invasive disease-free survival (IDFS); key secondary endpoints included distant relapse-free survival (DRFS), safety, and patient-reported outcomes (PROs). Results: Overall, 501 Chinese patients were included (abemaciclib + ET, n = 259; ET, n = 242). With a median follow-up of 53 months, the addition of abemaciclib to ET resulted in improvements in IDFS (estimated 5-year IDFS rate: 85.9% vs 79.1%; hazard ratio (HR), 0.65 (95% confidence interval (CI) 0.41–1.03)) and DRFS (estimated 5-year DRFS rate: 88.4% vs 82.3%; HR, 0.65 (95% CI, 0.39–1.07)). The most common grade ⩾3 treatment-emergent adverse events in the abemaciclib + ET versus ET groups were neutropenia (24.7% vs 0.8%) and leukopenia (22.4% vs 0.4%). Generally, no clinically meaningful difference in PROs (endocrine symptoms and fatigue) was observed between groups, except for diarrhea. Conclusion: At this prespecified OS interim analysis, which provides 5-year data, the addition of abemaciclib to ET in Chinese patients with high-risk HR+, HER2− EBC was associated with sustained and clinically meaningful improvements in IDFS and DRFS, with acceptable safety and tolerability profiles and minimal impact on PROs. These results represent the first full report of a CDK4/6 inhibitor in Chinese patients with EBC and support the positive benefit–risk profile of adjuvant abemaciclib + ET in Chinese patients. Trial registration: ClinicalTrials.gov identifier: NCT03155997 (first posted: May 16, 2017). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020

Author

Li, Jianbin, Wang, Haibo, Geng, Cuizhi, Liu, Zhenzhen, Lin, Ying, Nie, Jianyun, Sun, Gang, Ouyang, Quchang, Wang, Xiaojia, Li, Xingrui, Liu, Yinhua, Chen, Qianjun, Fu, Peifen, Yao, Feng, Chen, Jishang, Chen, Yiding, Zhao, Haidong, Yin, Yongmei, Zhang, Jingjie, Chen, Jiayi, Kong, Xiangshun, Cheng, Jing, Zhang, Haiqing, Peng, Shijun, Wang, Geng, Jin, Feng, Liu, Yunjiang, Wu, Gang, Sun, Shengrong, and Jiang, Zefei

Published
2020
Full Text
View/download PDF

37. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Jiang, Zefei, Li, Wei, Hu, Xichun, Zhang, Qingyuan, Sun, Tao, Cui, Shude, Wang, Shusen, Ouyang, Quchang, Yin, Yongmei, Geng, Cuizhi, Tong, Zhongsheng, Cheng, Ying, Pan, Yueyin, Sun, Yuping, Wang, Hong, Ouyang, Tao, Gu, Kangsheng, Feng, Jifeng, Wang, Xiaojia, Wang, Shubin, Liu, Tianshu, Gao, Jinghua, Cristofanilli, Massimo, Ning, Zhiqiang, and Lu, Xianping

Published
2019
Full Text
View/download PDF

43. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Author

Ma, Fei, primary, Yan, Min, additional, Li, Wei, additional, Ouyang, Quchang, additional, Tong, Zhongsheng, additional, Teng, Yuee, additional, Wang, Yongsheng, additional, Wang, Shusen, additional, Geng, Cuizhi, additional, Luo, Ting, additional, Zhong, Jincai, additional, Zhang, Qingyuan, additional, Liu, Qiang, additional, Zeng, Xiaohua, additional, Sun, Tao, additional, Mo, Qinguo, additional, Liu, Hu, additional, Cheng, Ying, additional, Cheng, Jing, additional, Wang, Xiaojia, additional, Nie, Jianyun, additional, Yang, Jin, additional, Wu, Xinhong, additional, Wang, Xinshuai, additional, Li, Huiping, additional, Ye, Changsheng, additional, Dong, Fangli, additional, Wu, Shuchao, additional, Zhu, Xiaoyu, additional, and Xu, Binghe, additional

Published
2023
Full Text
View/download PDF

44. OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Author

Xu, Binghe, primary, Ma, Fei, additional, Yan, Min, additional, Hu, Xichun, additional, Feng, Jifeng, additional, Ouyang, Quchang, additional, Tong, Zhongsheng, additional, Li, Huiping, additional, Zhang, Qingyuan, additional, Sun, Tao, additional, Wang, Xian, additional, Yin, Yongmei, additional, Cheng, Ying, additional, Li, Wei, additional, Chen, Chunxia, additional, and Rong, Shangyi, additional

Published
2023
Full Text
View/download PDF

47. Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study

Author

Li, Yiqun, primary, Tong, Zhongsheng, additional, Wu, Xinhong, additional, Ouyang, Quchang, additional, Cai, Li, additional, Li, Wei, additional, Yu, Zhiyong, additional, Han, Zhengxiang, additional, Wang, Xiaojia, additional, Li, Man, additional, Wang, Haibo, additional, Li, Li, additional, Yang, Jin, additional, Niu, Zhaofeng, additional, Wang, Qitang, additional, and Xu, Binghe, additional

Published
2023
Full Text
View/download PDF

48. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial

Author

Zhang, Qingyuan, primary, Li, Wei, additional, Hu, Xichun, additional, Sun, Tao, additional, Cui, Shude, additional, Wang, Shusen, additional, Ouyang, Quchang, additional, Yin, Yongmei, additional, Geng, Cuizhi, additional, Tong, Zhongsheng, additional, Cheng, Ying, additional, Ning, Zhiqiang, additional, and Jiang, Zefei, additional

Published
2023
Full Text
View/download PDF

49. Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.

Author

Yuan, Yang, primary, Zhang, Shaohua, additional, Wang, Tao, additional, Wang, Biyun, additional, Wang, Shusen, additional, Shi, Jing, additional, Sun, Tao, additional, Yin, Yongmei, additional, Ouyang, Quchang, additional, Li, Jianbin, additional, Wen, Yi, additional, Zhang, Lijun, additional, and Jiang, Zefei, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results